Enzyme-Resistant Pancreatic Polypeptide Analogs Stimulate Beta Cell Growth for Diabetes | Research

The takeaway

Novel enzyme-resistant pancreatic polypeptide analogs promoted pancreatic beta cell proliferation, representing a new peptide approach to restoring insulin-producing cells in diabetes.

Beta cells regrow
Novel PP analogs stimulated proliferation of insulin-producing pancreatic beta cells, addressing the root cause of diabetes

What the researchers found

Novel enzyme-resistant pancreatic polypeptide analogs promoted pancreatic beta cell proliferation, offering a potential peptide-based approach to restoring insulin-producing cell mass.

Why it matters

Diabetes fundamentally involves loss of insulin-producing beta cells. Finding a peptide that stimulates beta cell growth could enable regenerative treatments that restore the body's own insulin production — a cure-level approach.

The numbers in context

Five novel analogs designed with amino acid substitutions and fatty acid derivatization for enhanced stability and NPY4R activation.

How the study worked

Designed and synthesized enzyme-resistant PP analogs. Assessed enzymatic stability, receptor binding, and effects on pancreatic beta cell proliferation and function.

Who was studied

Mice treated with five novel enzyme-resistant PP analogs

What this study cannot tell us

Preclinical study. Beta cell proliferation in lab conditions may not translate to in vivo regeneration. Safety of chronic PP analog administration, especially effects on appetite and other NPY pathways, needs evaluation.

How to read the evidence

Preliminary evidence: preclinical study demonstrating a novel regenerative effect of engineered PP analogs on beta cells.

When this study was published

Published in 2024. Novel application of NPY-family peptide engineering for diabetes regeneration.

The bigger picture

The NPY family of peptides (NPY, PYY, PP) has diverse metabolic functions. Discovering that engineered PP analogs can stimulate beta cell regeneration adds a regenerative dimension to peptide-based diabetes treatment — complementing GLP-1 drugs that enhance existing beta cell function.

Questions still open

Could PP analogs restore beta cell mass in type 1 diabetes patients?
How do PP analogs interact with GLP-1 drugs — could they be combined?
What are the safety implications of stimulating cell proliferation near the pancreas?

Common questions

What is pancreatic polypeptide?

PP is a hormone from the NPY family released by the pancreas after eating. It helps regulate digestion and blood sugar. These engineered analogs retain PP's beneficial effects while resisting the enzymes that normally break it down, making them last longer in the body.

Could this cure diabetes?

If PP analogs can regenerate enough insulin-producing beta cells, they could theoretically restore the body's ability to make insulin — addressing the root cause of diabetes rather than just managing symptoms. However, much more research is needed, including human clinical trials.

Read the original research

Novel enzyme-resistant pancreatic polypeptide analogs evoke pancreatic beta-cell rest, enhance islet cell turnover, and inhibit food intake in mice.

BioFactors (Oxford, England), 50(6), 1101-1112

View on PubMed ↗Publisher’s paper ↗

Citation

Zhu, Wuyun; Tanday, Neil; Lafferty, Ryan A; Flatt, Peter R; Irwin, Nigel. (2024). Novel enzyme-resistant pancreatic polypeptide analogs evoke pancreatic beta-cell rest, enhance islet cell turnover, and inhibit food intake in mice.. BioFactors (Oxford, England), 50(6), 1101-1112. https://doi.org/10.1002/biof.2059